ReNetX Bio's Series A Round

ReNetX Bio raised a round of funding on April 09, 2018.

ReNetX Bio, fka Axerion Therapeutics, is developing therapeutics to treat injury and damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI) and glaucoma.…

Articles about ReNetX Bio's Series A Round: